CURIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.72 USD | -4.78% |
|
-3.91% | +23.29% |
| 05-07 | Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-07 | Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024 |
| Sales 2024 * | 9.7M 775M | Sales 2025 * | 10.52M 840M | Capitalization | 92.66M 7.4B |
|---|---|---|---|---|---|
| Net income 2024 * | -47M -3.75B | Net income 2025 * | -53M -4.23B | EV / Sales 2024 * | 9.55 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.81 x |
| P/E ratio 2024 * |
-2.08
x | P/E ratio 2025 * |
-3.23
x | Employees | 49 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Curis, Inc.
More recommendations
More press releases
| 1 day | -4.78% | ||
| 1 week | -3.91% | ||
| Current month | +2.41% | ||
| 1 month | +2.88% | ||
| 3 months | +46.64% | ||
| 6 months | +156.44% | ||
| Current year | +23.29% |
1 week
15.72
16.93
1 month
13.9916.99
Current year
8.2417.49
1 year
3.8019.60
3 years
3.80312.00
5 years
3.80348.00
10 years
3.80375.00
| Managers | Title | Age | Since |
|---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 28/03/16 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 25/07/22 |
| Chief Tech/Sci/R&D Officer | - | 02/01/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 31/10/03 |
Martyn Greenacre
CHM | Chairman | 82 | 13/02/00 |
James Dentzer
CEO | Chief Executive Officer | 57 | 28/03/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/05/24 | 15.72 | -4.78% | 12,065 |
| 09/05/24 | 16.51 | +0.98% | 27,636 |
| 08/05/24 | 16.35 | +0.93% | 15,118 |
| 07/05/24 | 16.2 | +0.19% | 17,446 |
| 06/05/24 | 16.17 | -1.16% | 6,608 |
Delayed Quote Nasdaq, May 10, 2024 at 09:00 pm
More quotes
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
14/05/2024
- Business Update Call
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.72
USD
Average target price
79.8
USD
Spread / Average Target
+407.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.29% | 92.66M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- CRIS Stock
